Biomarker: | BCR-ABL1 fusion |
---|---|
Cancer: | B Acute Lymphoblastic Leukemia |
Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) + S81694 (TTK inhibitor) |
Direction: | Sensitive |